| Literature DB >> 36209103 |
Irene Molina-de la Fuente1,2,3, Mulat Yimar4, Luz García5,6, Vicenta González5,6, Arancha Amor7, Melaku Anegagrie7, Agustín Benito5,6, Javier Martínez8, Marta Moreno9, Pedro Berzosa5,6.
Abstract
BACKGROUND: Although rapid diagnostic tests (RDTs) play a key role in malaria-control strategies, their efficacy has been threatened by deletion and genetic variability of the genes pfhrp2/3. This study aims to characterize the deletion, genetic patterns and diversity of these genes and their implication for malaria RDT effectiveness, as well as their genetic evolution in the Amhara region of Ethiopia.Entities:
Keywords: Deletions; Ethiopia; Malaria; Plasmodium falciparum; Rapid diagnostic test; pfhrp2
Mesh:
Substances:
Year: 2022 PMID: 36209103 PMCID: PMC9548178 DOI: 10.1186/s12936-022-04306-3
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 3.469
Fig. 1Map of collection sites in Ethiopia. The red dots correspond to the location of the four cities’ health centres where samples were collected
Fig. 2Methodological flow scheme. Microscopy diagnosis was confirmed by nested multiplex PCR, distinguishing P. falciparum, Plasmodium vivax, Plasmodium Ovale, and Plasmodium malaria. Four independent PCRs were run for the P. falciparum samples to detect deletions in exon 1–2 and exon 2 of pfhrp2 and pfhrp3. The deletion of any exon was confirmed by an absence of amplification after three PCR repetitions and the confirmation of maintained DNA quality. Samples that could not be confirmed for DNA quality were excluded from the analysis for that gene. Subsequent data analysis for the combined results was performed only with those samples included in the independent analysis for both genes. Additionally, a sub-sample lacking the deletion for exon 2 of both genes was sequenced and the genetic diversity and variation in amino-acid sequences analysed. Finally, a sub-sample of these sequences was used to predict the protein structure model and to locate the epitopes in the structure
Fig. 3Summary of results of molecular analysis of pfhrp2 and pfhrp3. Figure represents the different results in the independent experiments for exon 1–2 and 2 of both genes. Deletions samples: samples that did not amplify in the first PCR for the exon. Confirmed deletions: samples that did not amplify in three independent PCR experiments for the same specific gene, process called ‘repetition pfhrp2/3 PCR’ in the figure. Presence: samples that amplified at least one for a specific exon
Fig. 4Gel images of the full-length PCR of pfhrp2 and pfhrp3. Electrophoresis gel showed the result of the amplification for PCR combining exon 1–2 and exon 2, the expected fragment was around 900 base pairs as it could be observed in the positives controls placed at the end of the gel: 3D7, Dd2 and HB3. Negative controls for the first and second PCR were placed in the first two wells of the gel
Deletion patterns for exon 1–2 and exon 2 of pfhrp2 and pfhrp3 genes
| Exon 1–2 | Exon 2 | F (90% IC) | n (N) | |
|---|---|---|---|---|
| Complete deletion | − | − | 2.86 (1.49–5.22) | 8 (280) |
| Candidate partial deletion | − | + | 16.43 (12.94–20.58) | 46 (280) |
| Candidate partial deletion | + | − | 1.79 (0.76–3.86) | 5 (280) |
| Complete gene | + | + | 78.93 (74.46–82.82) | 221 (280) |
| Complete deletion | − | − | 17.64 (13.76–22.29) | 42 (238) |
| Candidate partial deletion | − | + | 50.84 (45.32–56.34) | 121 (238) |
| Candidate partial deletion | + | − | 0.84 (0.18–2.81) | 2 (238) |
| Complete gene | + | + | 30.67 (25.16–36.80) | 73 (238) |
Exon 1–2 −: samples that did not amplify for exon 1–2; Exon 1–2 +: samples that amplified for exon 1–2; Exon 2 −: samples that did not amplify for exon 2; Exon 2 +: samples that amplified for exon 2
Frequencies of deletion patterns based on deletion/presence of exon 1–2 and exon 2 of pfhrp2 and pfhrp3 genes
| F (90% IC) | Number of isolates (N = 219) | ||||
|---|---|---|---|---|---|
| Exon 1–2 | Exon 2 | Exon 1–2 | Exon 2 | ||
| + | + | + | + | 30.59 (25.52–36.16) | 67 |
| − | − | + | + | 0 | 0 |
| + | + | − | − | 13.70 (10.12–18.22) | 30 |
| − | + | − | + | 8.68 (5.84–12.59) | 19 |
| + | − | + | − | 0.46 (0.01–2.38) | 1 |
| − | − | − | − | 1.37 (0.42–3.69) | 3 |
Genetic diversity of pfhrp2 and pfhrp3 by geographical location
| Health centre | No. of isolates | S | H | K | π | Θ per site | Θ per sequence |
|---|---|---|---|---|---|---|---|
| Overall | 95 | 532 | 92 | 63.36 | 0.158 | 0.162 | 135.53 |
| Tis Abay | 57 | 419 | 55 | 61.32 | 0.150 | 0.147 | 108.07 |
| Bahir Dar | 16 | 305 | 16 | 65.13 | 0.175 | 0.180 | 108.73 |
| Zenzelima | 3 | 532 | 3 | 63.36 | 0.159 | 0.162 | 135.54 |
| Meshenti | 19 | 320 | 19 | 65.46 | 0.163 | 0.151 | 114.65 |
| Overall | 79 | 188 | 77 | 10.223 | 0.027 | 0.083 | 49.02 |
| Tis Abay | 50 | 140 | 48 | 9.01 | 0.025 | 0.071 | 41.75 |
| Bahir Dar | 13 | 91 | 13 | 13.41 | 0.035 | 0.068 | 34.29 |
| Meshenti | 16 | 57 | 16 | 10.11 | 0.023 | 0.049 | 25.06 |
Results were obtained using pairwise comparison, 4,465 pairwise comparisons have been performed and the average number of sites analysed by comparison was 405,72, total number of sites were 916
S: number of segregating sites; H: number of different haplotypes; K: average number of nucleotide differences; π: nucleotide diversity; Θ per site: genetic diversity per site; Θ per sequence: genetic diversity per sequence
Fig. 5Bayesian inference phylogenetic tree for pfhrp2 (a) and pfhrp3 (b) sequences. The nucleotide sequences of exon 2 for both genes, with fragments ranging from 300 to 700 base pairs, were analysed. This analysis combined nucleotide sequences from this article, represented with a dot (n = 95 for pfhrp2 and n = 79 for pfhrp3) and sequences from bordering countries published in previous studies, represented with dots with different shapes (n = 33 for pfhrp2 and n = 33 for pfhrp3). Coloured dots indicate the geographical origin of the samples. Phylogenetic trees were performed using Bayesian inference
Occurrence and number of amino-acid repeat types in pfhrp2 and pfhrp3 sequences
| Repeat types | Amino acid repeat | Pfhrp2 | Pfhrp3 | ||
|---|---|---|---|---|---|
| Range of no. of repeats | Occurrence (%) | Range of no. of repeats | Occurrence (%) | ||
| Type 1 | AHHAHHVAD | 0–5 | 42 | 0–2 | 63.75 |
| Type 2 | AHHAHHAAD | 1–16 | 0 | 0 | |
| Type 3 | AHHAHHAAY | 0–2 | 83 | 0 | 0 |
| Type 4 | AHH | 0–18 | 80 | 0–6 | 88.75 |
| Type 5 | AHHAHHASD | 0–2 | 67 | 0 | 0 |
| Type 6 | AHHATD | 0–7 | 75 | 0 | 0 |
| Type 7 | AHHAAD | 1–8 | 0–1 | 95.00 | |
| Type 8 | AHHAAY | 0–2 | 90 | 0 | 0 |
| Type 9 | AAY | 0–1 | 3 | 0 | 0 |
| Type 10 | AHHAAAHHATD | 0–3 | 40 | 0 | 0 |
| Type 11 | AHN | 0 | 0 | 0 | 0 |
| Type 12 | AHHAAAHHEAATH | 0–1 | 35 | 0 | 0 |
| Type 13 | AHHASD | 0–2 | 18 | 0 | 0 |
| Type 14 | AHHAHHATD | 0–1 | 13 | 0 | 0 |
| Type 15 | AHHAHHAAN | 0 | 0 | 0–1 | 68.75 |
| Type 16 | AHHAAN | 0–1 | 1 | 0–17 | 98.75 |
| Type 17 | AHHDG | 0 | 0 | 0–8 | 90.00 |
| Type 18 | AHHDD | 0 | 0 | 0–4 | 88.75 |
| Type 19 | AHHAA | 0–2 | 23 | 0–1 | 1.25 |
| Type 20 | SHHDD | 0 | 0 | 0–1 | 87.5 |
| Type 21 | AHHAHHATY | 0 | 0 | 0 | 0 |
| Type 22 | AHHAHHAGD | 0 | 0 | 0 | 0 |
| Type 23 | ARHAAD | 0 | 0 | 0 | 0 |
| Type 24 | AHHTHHAAD | 0 | 0 | 0 | 0 |
Frequency of major epitopes in pfhrp2 and pfhrp3 exon-2 targeted by MAbs in HRP2-based RDT
| MAb | Major epitope | ||||
|---|---|---|---|---|---|
| Frequency (%) | Median frequency (n) | Frequency (%) | Median frequency (n) | ||
| 3A4 | AHHAHHA | 100 | 14 | 70 | 1 |
| 2G12-1C12 | DAHHAADAHH | 99.06 | 4 | 0 | 0 |
| 1E1-A9 | AHHAHHV | 42.06 | 0 | 65 | 1 |
| A6-4 | HATDAHH | 84.11 | 3 | 0 | 0 |
| C1-13 | AHHAADAHH | 100 | 13 | 4 | 0 |
| N7 | DAHHAADAHHA | 99.06 | 4 | 0 | 0 |
| PTL-3 | YAHHAHHA | 95.33 | 2 | 0 | 0 |
| S2-5 | AHHASDAHHA | 84.11 | 1 | 0 | 0 |
| TC-10 | TDAHHAADAHHAADA | 54.21 | 1 | 0 | 0 |
| C2-3 | HAHHAHHAADAHH | 43.93 | 0 | 0 | 0 |
| Genway | AYAHHAHHAAY | 0 | 0 | 0 | 0 |
Fig. 6Secondary structure, solvent surface area and mapping of epitopes in the PfHRP2 protein structure models. Model of structure was assessed by RSMD measured with Å. Solvent surface area is coloured gradually according to electrostatic potential from − 5 kT/e (red) to + 5 kT/e (blue). NA: Not applicable due to absence of epitope in the sequence
Fig. 7Secondary structure, solvent surface area and mapping of epitopes in the PfHRP3 protein structure models. Model of structure was assessed RSMD measured with Å. Solvent surface area is coloured gradually according to electrostatic potential from − 5 kT/e (red) to + 5 kT/e (blue). NA: Not applicable due to absence of epitope in the sequence